APA

Diluvio G., Del Gaudio F., Giuli M. V., Franciosa G., Giuliani E., Palermo R., Besharat Z. M., Pignataro M. G., Vacca A., d'Amati G., Maroder M., Talora C., Capalbo C., Bellavia D. & Checquolo S. (2018). NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. : Oncogenesis.

Chicago

Diluvio Giulia, Del Gaudio Francesca, Giuli Maria Valeria, Franciosa Giulia, Giuliani Eugenia, Palermo Rocco, Besharat Zein Mersini, Pignataro Maria Gemma, Vacca Alessandra, d'Amati Giulia, Maroder Marella, Talora Claudio, Capalbo Carlo, Bellavia Diana and Checquolo Saula. 2018. NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. : Oncogenesis.

Harvard

Diluvio G., Del Gaudio F., Giuli M. V., Franciosa G., Giuliani E., Palermo R., Besharat Z. M., Pignataro M. G., Vacca A., d'Amati G., Maroder M., Talora C., Capalbo C., Bellavia D. and Checquolo S. (2018). NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. : Oncogenesis.

MLA

Diluvio Giulia, Del Gaudio Francesca, Giuli Maria Valeria, Franciosa Giulia, Giuliani Eugenia, Palermo Rocco, Besharat Zein Mersini, Pignataro Maria Gemma, Vacca Alessandra, d'Amati Giulia, Maroder Marella, Talora Claudio, Capalbo Carlo, Bellavia Diana and Checquolo Saula. NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. : Oncogenesis. 2018.